Barbora Vakrmanova

Barbora Vakrmanova

Auto-generated profile, based on publicly available information

Barbora Vakrmanova

Second Faculty of Medicine, Charles University Prague, University Hospital Motol, Czech Republic

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2018 in Blood
Verified
Journal Article
Closed access
PDF file
OHOndrej Hrusak
Ondrej Hrusak
VHValerie de Haas
Valerie de Haas
JSJitka Stancikova
Jitka Stancikova
BVBarbora Vakrmanova
Barbora Vakrmanova
IJIveta Janotova
Iveta Janotova
JSJan Stary
Jan Stary
Despite attempts to improve the definitions of ambiguous leukemia (ALAL) during the last two decades, general therapy recommendations are missing. Herein, we report a large cohort of children with ALAL and propose a treatment strategy. A retrospective multinational study iBFM-AMBI2012 on 233 cases of pediatric ALAL patients is presented. Survival statistics were used to compare the prognosis of subsets and types of treatment. Five-year event-free survival (5yEFS) of patients with acute lymphoblastic leukemia (ALL)-type primary therapy (80±4%) was superior to that of children who received acute myeloid leukemia (AML)-type or combined-type treatments (36±7.2% and 50±12%, respectively). When ALL- or AML-specific gene fusions were excluded, 5yEFS of CD19pos leukemia was 83±5.3% on ALL-type primary treatment compared to 0±0% and 28±14% on AML-type and combined-type primary treatment, respectively. Superiority of ALL-type treatment was documented in single-population mixed phenotype ALAL (using WHO and/or EGIL definitions), and in the bilineal ALAL. Treatment with ALL-type protocols is recommended for the majority of pediatric patients with ALAL, including cases with CD19pos ALAL. AML-type of treatment is preferred in a minority of ALAL cases with CD19neg and no other lymphoid features ALALs. No overall benefit of transplantation was documented and it could be introduced in some patients with a poor response to treatment. As no clear indicator was found for a change to the treatment type, this is to be considered only in cases with 5% blast or greater after remission induction. The results provide a basis for a prospective trial. Key points The largest cohort of ambiguous leukemias to date reveals a better prognosis of children who started on lymphoid-directed treatment. Myeloid type of primary treatment correlated with dismal outcomes in CD19pos leukemias.

20 May 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
BVBarbora Vakrmanová
Barbora Vakrmanová
MNMichaela Nováková
Michaela Nováková
PŘPetr Říha
Petr Říha
MŽMarkéta Žaliová
Markéta Žaliová
EFEva Froňková
Eva Froňková
LŠLucie Šrámková
Lucie Šrámková

23 May 2018
Verified
Dataset
Closed access
JSJan Starý
Jan Starý
BVBarbora Vakrmanova
Barbora Vakrmanova
β-thalassemia is one of the most prevalent monogenetic disorders worldwide. In the most severe form – transfusion-dependent β-thalassemia – patients require long-term red cell transfusions for survival. The only potentially curative option is stem cell transplantation, reserved only for young children with HLA-identical donor. Thompson et al. present a study of 22 patients with transfusion-dependent β-thalassemia...

28 January 2019
Verified
Dataset
Closed access
JSJan Starý
Jan Starý
BVBarbora Vakrmanova
Barbora Vakrmanova
B cell precursor acute lymphoblastic leukemia (BCP ALL), the most common malignancy in children, consists of many genetic subtypes with different prognosis. Using RNA sequencing (RNAseq) helped identify new genetic subtypes recently -- DUX4, ZNFR384, BCR-ABL1-like, etc. Despite this progress, about 10% of BCP ALL cases have unclear genetic background. Discovering new genetic subtypes and their prognosis are important for stratification and potential use of target therapy. Using RNAseq in 1998 childhood and adult BCP ALLs, Mullighan and his team defined new BCP ALL subtypes -- PAX5alt and PAX5 p.Pro80Arg. They showed that PAX5 alterations could be initiating, sub-type defining events, and not secondary events as has been considered in previous studies. According to the results, PAX5alt and PAX5 p.Pro80Arg have inferior outcomes in children. The authors also determined the most common deregulated pathways in each subtype. Overall, Mullighan's team shows the importance of RNAseq in defining new genetic subtypes, which can lead to better stratification of patients.

11 December 2017
Verified
Dataset
Closed access
JSJan Starý
Jan Starý
BVBarbora Vakrmanova
Barbora Vakrmanova
Bone marrow failure (BMF) in children is often suspected to be inherited but many patients remain undiagnosed. The authors studied a large cohort (179) of these undiagnosed patients (Fanconi anemia excluded). Using whole exome sequencing (WES) of skin fibroblasts (which secured the germline nature of identified mutations) combined with clinical analysis, they provided a molecular diagnosis in 48% patients of their cohort. They found some new genes that are not usually mentioned at BMF diagnosis (SAMD9, SAMD9L, ERCC6L2, MECOM) and some genes that could possibly contribute to BMF (BRCA2, TP53), but further investigation and functional tests are needed. Identifying new genes, their frequency and clinical presentations will be useful in obtaining an accurate genetic diagnosis at medical evaluation. For example, patients with SAMD9/SAMD9L mutations might improve spontaneously. Longer follow-up of these patients is necessary for decisions on bone marrow transplantation. This paper is of clinical importance because it is the basis for further investigations on inherited BMF pathogenesis, classification and risk prediction.

19 June 2020
Verified
Dataset
Closed access
JSJan Starý
Jan Starý
BVBarbora Vakrmanova
Barbora Vakrmanova
Cytokine storm syndromes (CSS) are severe hyperinflammatory conditions characterized by excessive immune system activation leading to organ damage and death. Hemophagocytic lymphohistiocytosis (HLH), a disease often associated with inherited defects in cell-mediated cytotoxicity, serves as a prototypical CSS for which the five-year survival is only 60%. Frontline therapy for HLH consists of the glucocorticoid dexamethasone (DEX) and the chemotherapeutic agent etoposide. Many patients, however, are refractory to this treatment or relapse after an initial response. Notably, many cytokines that are elevated in HLH activate the JAK/STAT pathway, and the JAK1/2 inhibitor ruxolitinib (RUX) has shown efficacy in murine HLH models and humans with refractory disease. We recently reported that cytokine-induced JAK/STAT signaling mediates DEX resistance in T cell acute lymphoblastic leukemia (T-ALL) cells, and that this could be effectively reversed by RUX. Based on these findings, we hypothesized that cytokine-mediated JAK/STAT signaling might similarly contribute to DEX resistance in HLH and that RUX treatment would overcome this phenomenon. Using ex vivo assays, a murine model of HLH, and primary patient samples, we demonstrate that the hypercytokinemia of HLH reduces the apoptotic potential of CD8 T cells leading to relative DEX resistance. Upon exposure to RUX, this apoptotic potential is restored, thereby sensitizing CD8 T cells to DEX-induced apoptosis in vitro and significantly reducing tissue immunopathology and HLH disease manifestations in vivo. Our findings provide rationale for combining DEX and RUX to enhance the lymphotoxic effects of DEX and thus improve the outcomes for patients with HLH and related CSS. Copyright © 2020 American Society of Hematology.